MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 30, 2007; DOI: 10.1124/mol.107.041640


0026-895X/08/7302-305-313$20.00
Mol Pharmacol 73:305-313, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.041640v1
73/2/305    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hussainzada, N.
Right arrow Articles by Swaan, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hussainzada, N.
Right arrow Articles by Swaan, P. W.

Conformational Flexibility of Helix VI Is Essential for Substrate Permeation of the Human Apical Sodium-Dependent Bile Acid Transporter

Naissan Hussainzada, Akash Khandewal, and Peter W. Swaan

Department of Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland

The present study characterizes the methanethiosulfonate (MTS) inhibition profiles of 26 consecutive cysteine-substituted mutants comprising transmembrane (TM) helix 6 of the human apical Na+-dependent bile acid transporter (SLC10A2). TM6 is linked exofacially to TM7 via extracellular loop 3. TM7 was identified previously as lining part of the substrate permeation path ( Mol Pharmacol 70: 1565, 2006[Abstract/Free Full Text] ). Most TM6 cysteine replacements were well tolerated, except for five residues with either severely hampered (I229C, G249C) or abolished (P234C, G237C, G241C) activity. Disruption of protein synthesis or folding and stability may account for lack of activity for mutant P234C. Subsequent Pro234 amino acid replacement reveals its participation in both structural and functional aspects of the transport cycle. Application of polar MTS reagents (1 mM) significantly inhibited the activity of six mutants (V235C, S239C, F242C, R246C, A248C, and Y253C), for which rates of modification were almost fully reversed (except Y253C) upon inclusion of bile acid substrates or removal of Na+ from the MTS preincubation medium. Activity assessments at equilibrative [Na+] revealed numerous Na+-sensitive residues, suggesting their proximity in or around Na+ interaction sites. In silico modeling reveals the intimate and potentially cooperative orientation of MTS-accessible TM6 residues toward functionally important TM7 amino acids, substantiating TM6 participation during the transport cycle. We conclude a functional requirement for helical flexibility imparted by Pro234, Gly237, and Gly241, probably forming a "conformational switch" requisite for substrate turnover; meanwhile, MTS-accessible residues, which line a helical face spatially distinct from this switch, may participate during substrate permeation.


Received September 7, 2007; accepted October 29, 2007

Address correspondence to: Dr. Peter W. Swaan, Department of Pharmaceutical Sciences, University of Maryland, 621 HSF-II, 20 Penn Street, Baltimore, MD 21201. E-mail: pswaan{at}rx.umaryland.edu




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
N. Hussainzada, T. C. Da Silva, E. Y. Zhang, and P. W. Swaan
Conserved Aspartic Acid Residues Lining the Extracellular Loop I of Sodium-coupled Bile Acid Transporter ASBT Interact with Na+ and 7{alpha}-OH Moieties on the Ligand Cholestane Skeleton
J. Biol. Chem., July 25, 2008; 283(30): 20653 - 20663.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics